Loading...
•
Jun 30, 2022
Enanta Pharmaceuticals Q3 2022 Earnings Report
Reported financial results for the fiscal third quarter ended June 30, 2022.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $19.5 million for the quarter, primarily from royalty revenue. The net loss for the quarter was $31.7 million, or $1.53 per diluted common share. Cash, cash equivalents, and marketable securities totaled $292.7 million at the end of the quarter.
Presented positive Phase 1 study data for EDP-235, a Coronavirus 3CL Protease Inhibitor, with a Phase 2 study planned for Q4 2022.
Progressing Respiratory Syncytial Virus (RSV) Portfolio with a Phase 2 study of EDP-938 in High-Risk Adults and a Phase 1 study of EDP-323 planned for Q4 2022.
Royalty Revenue for the Quarter was $19.5 Million.
Filed a suit against Pfizer for infringement of U.S. Patent No. 11,358,953 regarding Paxlovid.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and short-term and long-term marketable securities, as well as its continuing royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs for the next two years.